Company Name:
Sun Pharmaceutical Industries Limited (Sun Pharma)
Company Summary:
Established in 1983, Sun Pharma has grown into India’s largest pharma company and the world’s fourth-largest specialty generic pharmaceutical corporation. With a diversified portfolio of over 2,000 formulations across acute and chronic therapeutic areas, the company serves more than 100 countries with affordable, high-quality medicines. (turn0search12)
It is driven by innovation, with 6–8% of revenue invested annually in R&D, supported by more than 3,000 scientists. (turn0search8)
Company CEO / Chairman:
Dilip Shanghvi – Founder, Chairman & Managing Director. He holds a majority stake and has led strategic acquisitions including Ranbaxy and Taro, positioning Sun Pharma as a global leader. (turn0search4)
Industry:
Pharmaceuticals (Specialty Generics, Branded Generics, APIs, OTC, Dermatology, Ophthalmology, Cardiology, Oncology, etc.) (turn0search8)
Ownership Type:
Publicly listed (BSE & NSE, part of NIFTY 50). Approximately 54–60% owned by Dilip Shanghvi and family. (turn0search12, turn0search17)
Manufacturing Facilities:
Operates 43 manufacturing sites across India and key global markets (USA, Europe, Asia, Africa, Australia) producing APIs, complex generics, and formulations. (turn0search12, turn0reddit20)
Product Portfolio:
Offers over 2,000 molecules in multiple dosage forms—including tablets, injectables, inhalers, and OTCs—across diverse therapeutic categories. (turn0search8, turn0reddit19)
R&D Focus:
R&D investments account for ~6–8% of sales. Development includes specialty drugs, differentiated generics (e.g., liposomal, inhalers, lyophilized injections), and novel formulation platforms. (turn0search8)
Global Presence:
Supplies medicines to more than 100 countries, with key revenue contributions from the US (≈31%), India (≈32%), emerging markets (≈18%), and developed markets globally (≈19%). (turn0reddit19, turn0search12)